MSD has fleshed out its cardiovascular disease pipeline by licensing an oral Lp (a) inhibitor from China's Jiangsu Hengrui ...

The aggregate gross proceeds to Benitec from the underwritten offering and the concurrent registered direct offering are expected to be approximately $30 million, prior to deducting underwriting ...

RNAi -- functions specifically to silence, or deactivate, genes. Among other applications, it promises to be groundbreaking ...

Silexion Therapeutics completes development plan for next-generation siRNA candidate SIL204; plans to present at 2025 NeauxCancer Conference: Grand Cayman, Cayman Islands Tuesday, ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Represents first project to enter the ECO Synthesis™ Innovation LabCore enzymes for ECO Synthesis™ technology have transitioned from research ...

Arrowhead Pharmaceuticals, Inc. shines with 19 clinical programs, strategic partnerships, and promising RNAi data. Click for ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...

Alnylam's Amvuttra enters ATTR-CM drug race, and Expedition Therapeutics seeks to bring Chinese drugs to the U.S.

The drug was already sold for TTR amyloidosis with polyneuropathy, and now is available to patients with hereditary or wild-type ATTR-CM.

In terms of safety and tolerability, the most common adverse reactions in patients treated with Amvuttra were pain in ...